MECHANISM OF INCR PLASMA APO A1 LEVELS BY ESTROGENS

雌激素影响 INCR 血浆 APO A1 水平的机制

• 批准号: 6275693
• 负责人: ERNST JOHN SCHAEFER
• 金额: $ 4.05万
• 依托单位: TUFTS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6275693
• 关键词: apolipoproteins; blood lipoprotein metabolism; clinical research; coronary disorder; disease /disorder proneness /risk; estrogens; female; hormone regulation /control mechanism; hormone therapy; human subject; human therapy evaluation; medroxyprogesterone; postmenopause

Postmenopausal women are at higher risk of coronary heart disease (CHD) than premenopausal women, even after controlling for age-effects. However, estrogen replacement therapy significantly lowers the risk of CHD in postmenopausal women. With the study, we propose to determine the kinetics of apolipoprotein A-I, the major protein component of high density lipoproteins, in postmenopausal women undergoing a placebo- controlled, randomized treatment with each of the following regimens: a. placebo; b. 0.625mg/d conjugated estrogens; c. 0.625mg/d conjugated estrogens + 2.5 mg/d medroxyprogesterone acetate. The kinetics of apo A-I will be determined by stable isotope techniques. The low dose estrogen (b) and the estrogen-progestin combination (c) are frequently prescribed ro postmenopausal women as hormone replacement therapy, but there are no studies comparing the effects of these two treatments on plasma lipid metabolism and apolipoprotein kinetics.

绝经后妇女患冠心病的风险更高 比绝经前的女性更高，即使在控制了年龄效应之后也是如此。 然而，雌激素替代疗法显著降低了患冠心病的风险。 在绝经后妇女中。通过这项研究，我们建议确定 HIGH的主要蛋白质组分载脂蛋白A-I的动力学 接受安慰剂治疗的绝经后妇女的密度脂蛋白- 采用以下每种方案的随机对照治疗： A.安慰剂； B.结合雌激素0.625 mg/d； C.0.625 mg/d结合雌激素+2.5 mg/d醋酸甲羟孕酮。 载脂蛋白A-I的动力学将用稳定同位素技术测定。 低剂量雌激素(B)和雌孕激素组合(C)是 绝经后妇女作为激素替代的常用处方 治疗，但没有研究比较这两种疗法的效果 治疗对血脂代谢和载脂蛋白动力学的影响。